Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Phase 3 study is expected to be substantially funded ... Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing ...

A new study found that 9.1% of medical device AEs were reported to the FDA 180 days later than required over a three-year ...

Icon PLC, the Irish-headquartered clinical research giant, has warned the markets that a large Covid-19 vaccine study it recently told investors about was delayed by its sponsor. In February, CEO ...

Under normal circumstances, the study of health problems after COVID vaccinations posted online on Feb. 25 might not have ...

2024 Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage ...

Key Insights Significantly high institutional ownership implies Legal & General Group's stock price is sensitive ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Satellites come in all shapes and sizes, but there aren't any that look quite like SPHEREx, an infrared observatory NASA ...

With their music continuing to entertain fans all over the world, Pearson recently passed away at 60 years old. Dealing with several health issues over the recent years, Pearson suffered from diabetes ...

Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint ...

Investing.com -- Shares of MeiraGTx Holdings plc (Nasdaq: NASDAQ: MGTX) climbed 13% following the announcement of a strategic collaboration with Hologen AI, aimed at accelerating the Phase 3 ...